Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non‐EML4‐ALK rearrangements detected from cerebrospinal fluid: A case report

Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC

(2019) Mei-Mei Zheng et al.   Journal of Thoracic Oncology

Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy

(2018) Y S Li et al.   ANNALS OF ONCOLOGY

Leptomeningeal metastases in non-small-cell lung cancer

(2018) Haiying Cheng et al.   LANCET ONCOLOGY

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

(2018) Benjamin J Solomon et al.   LANCET ONCOLOGY

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK -positive Non-Small Cell Lung Cancer

(2017) James Chih-Hsin Yang et al.   Journal of Thoracic Oncology

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

(2017) Toyoaki Hida et al.   LANCET

Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non-small-cell lung cancer with or without prior crizotinib therapy

(2016) Toyoaki Hida et al.   CANCER SCIENCE

Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer Relapsing on Standard Dose Alectinib

(2016) Justin F. Gainor et al.   Journal of Thoracic Oncology

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

(2013) Takashi Seto et al.   LANCET ONCOLOGY

Crizotinib for ALK-Rearranged Non-Small Cell Lung Cancer: A New Targeted Therapy for a New Target

(2012) L. Gandhi et al.   CLINICAL CANCER RESEARCH